Literature DB >> 27504759

Biogen and UPenn join forces to commercialize gene therapies.

Cormac Sheridan.   

Abstract

Year:  2016        PMID： 27504759     DOI： 10.1038/nbt0816-791

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  $1-million price tag set for Glybera gene therapy.

Authors:  Chris Morrison
Journal:  Nat Biotechnol       Date:  2015-03       Impact factor: 54.908

2.  Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside.

Authors:  Valerie Ferreira; Harald Petry; Florence Salmon
Journal:  Front Immunol       Date:  2014-03-03       Impact factor: 7.561

3.  A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice.

Authors:  Yang Yang; Lili Wang; Peter Bell; Deirdre McMenamin; Zhenning He; John White; Hongwei Yu; Chenyu Xu; Hiroki Morizono; Kiran Musunuru; Mark L Batshaw; James M Wilson
Journal:  Nat Biotechnol       Date:  2016-02-01       Impact factor: 54.908
  3 in total
  2 in total

1.  Early clinical data raise the bar for hemophilia gene therapies.

Authors:  Elie Dolgin
Journal:  Nat Biotechnol       Date:  2016-10-11       Impact factor: 54.908

2.  Novartis snaps up Selexys for sickle cell.

Authors:  Chris Morrison
Journal:  Nat Biotechnol       Date:  2017-02-08       Impact factor: 54.908
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.